A spontaneous report was received from a Health canada via Health professional concerning a Female patient. Concomitant medications included paracetamol, ramipril, amlodipine besilate, hydrochlorothiazide, candesartan cilexetil, levothyroxine sodium, ergocalciferol, ezetimibe, lisinopril, methylprednisolone, prednisone, sitagliptin phosphate, rosuvastatin calcium and levothyroxine sodium.Patients relevant history and concurrent disease were not available.The patient had been receiving oral Nexium (Esomeprazole magnesium), started on an unknown date, intra-articular Depo-medrol (Methylprednisolone acetate) for product used for unknown indication, started on an unknown date, unknown Diamicron (Gliclazide) for product used for unknown indication, started on an unknown date, unknown Domperidone (Domperidone) for product used for unknown indication, started on an unknown date, subcutaneous Lantus (Insulin glargine) for product used for unknown indication, started on an unknown date, unknown Lyrica (Pregabalin) for product used for unknown indication, started on an unknown date and intravenous (not otherwise specified) Rituxan (Rituximab), 1000.0 milligrams, unknown for product used for unknown indication, started on an unknown date.It was reported that a patient had arthritis (preferred term: arthritis) and her condition aggravated (preferred term: condition aggravated). Patient also had coronary artery occlusion (preferred term: coronary artery occlusion).Action taken with all suspect drugs were unknown.The outcome of the event of arthritis, condition aggravated and coronary artery occlusion were unknown.The reporter has assessed the events of arthritis, condition aggravated and coronary artery occlusion to be serious with seriousness criteria of important medical event.